Darunavir

China [CN]

Derenavir is a new non-peptide antiretroviral protease inhibitor for the treatment of AIDS. It was first successfully developed by Tibotec, the Icelandic branch of Johnson & Johnson Pharmaceuticals. It is currently the protease inhibitor with the highest bioavailability among the six protease inhibitors (saquinavir, ritonavir, indenavir, nafenavir, enironavir and ABT378/r). It works by inhibiting the protease of the virus by blocking the formation process of new and mature viral particles released from the surface of infected host cells. When this product is used for a long time, it usually can reduce the HIV viral vector in the blood, increase the count of CD4 cells, lower the chance of contracting AIDS, improve the quality of life and prolong life. This drug is suitable for adults infected with the HIV virus who have not responded to existing antiretroviral drugs. It must be used in combination with a low dose of ritonavir Chemicalbook or other antiretroviral preparations to enhance the efficacy. Its antiviral activity in vitro can be evaluated by combating acute and chronic infected lymphoblasts and lymphocytes in peripheral systemic blood. Its IC50 is 0.012-0.08mmol/L for acute infected cells and 0.41mmol/L for chronic infected cells. Oral medication. The recommended dose is 1200mg each time, twice a day. The dosage should be reduced for patients with mild to moderate liver dysfunction and those with poor kidney function. The adverse reactions of derenavir mainly include gastrointestinal reactions, flushing, pruritus, numbness around the mouth, depression, mood disorders, taste disorders, etc. This product is not recommended for patients with moderate to severe liver dysfunction. As this component contains sulfonamide groups, it is contraindicated for those allergic to sulfonamides and for those allergic to any component in this prescription.